|
Lilly Asian Ventures |
 |
|
|
 |
 |
 |
    |
 |
 |
 |
HD Biosciences (HDB) is a leading China-based biology CRO company. Founded in 2002, HDB specializes in conducting assay development and high throughput screening (HTS) services for pharmaceutical and biotech clients and has provided services to clients including 5 out of the 10 world’s largest multinational pharmaceutical companies. HDB offers HTS assay development and screening services covering all major therapeutic targets, including GPCR, kinase and ion channels. HDB also conducts in vitro ADME and early toxicology (hERG and CYP450 screening) studies. HDB is expanding its leadership into more comprehensive pre-clinical biology service areas to better serve industrial clients’ needs. The company is building capabilities including biomarker profiling, in vivo biology, DMPK and bio-analytical chemistry services. Other investors include: Pfizer Ventures and the Morningside Group.
CITIC Pharmaceuticals CITIC Pharmaceutical is a major pharmaceutical distribution companies in China. Founded in 1993, the company is headquartered in Beijing and employs approximately 600 people. The company is a distributor for most multinational pharmaceutical companies in China. As one of the largest drug distributor in China, CITIC Pharmaceuticals has consistently outgrown its competitors and is well positioned in the rapidly consolidating medical distribution industry. Other investors include: Bioveda China and New Enterprise Associates.
Novast Novast is a leading specialty pharmaceutical company that develops and manufactures prescription drugs in final dosage form for highly regulated markets worldwide, including USA and Europe. Currently, Novast is focusing on the generic versions of controlled-release and other niche pharmaceutical products that have few competitors due to technical barriers. Founded in 2004, the company has built cGMP manufacturing facilities in Nantong, China. Other investors include: Bioveda China, New Enterprise Associates, Qi Ming Ventures, and SAIF Partners.
Chipscreen Biosciences Chipscreen Biosciences is a clinical stage biotech company that is developing innovative therapies for cancer and metabolic syndrome. Among its late stage pipeline is CS055, a best-in-class histone deacetylase inhibitor with global patent, is currently in Phase II/III clinical trials for solid tumors. Other investors include: Capitalbio Sciences, Vertex Technology Fund, Beijing Venture Capital, Teda Ventures, and SBI E2-Capital.
Beta Pharma Zhejiang Beta Pharma Inc., founded in 2003, is a Chinese biotech company focused on the development of therapies for cancer and inflammatory diseases. The company has a portfolio of compounds in its discovery and development pipeline, including Icotinib Hydrochloride, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor currently in phase III clinical development for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Beta Pharma is headquartered in Hangzhou Yuhang High-tech Park, Zhejiang Province, with its R&D center located in Beijing.
|
|
|
|
|
